Liquidity and Capital Resources (Details)						1 Months Ended	5 Months Ended	6 Months Ended
	Jun. 16, 2022 USD ($) shares	Jun. 15, 2022 USD ($) shares	Jun. 02, 2022 USD ($)	May 30, 2022 $ / shares shares	Apr. 06, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) $ / shares shares	Dec. 08, 2021 businessDay $ / shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Apr. 08, 2022 USD ($)	Dec. 31, 2021 USD ($)
Liquidity and Going Concern Considerations [Line Items]
Cash and Cash Equivalents								$ 30,780,000			$ 13,280,000
Working capital								28,700,000
Net cash used in operating activities								(15,718,000)	$ (17,433,000)
Minimum cash covenant								10,000,000
Stock issuance costs			$ 100,000					$ 106,000	$ 0
Proceeds from sale of equity, net			14,900,000
Period to regain Nasdaq minimum bid requirements							180 days
Common stock, closing bid price (at least) (in dollars per share) | $ / shares							$ 1.00
Number of consecutive business days (minimum) | businessDay							10
Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Consideration received					$ 15,000,000
Stock issuance costs					100,000
Proceeds from sale of equity, net					14,900,000
Registered Direct Offering Warrants
Liquidity and Going Concern Considerations [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) | shares				7,788,480
Exercise price of warrant (in dollars per share) | $ / shares				$ 0.0001
PIPE Purchase Agreement Pre-Funded Warrant
Liquidity and Going Concern Considerations [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) | shares				1,267,897
Exercise price of warrant (in dollars per share) | $ / shares				$ 0.0001
PIPE Purchase Agreement Warrant
Liquidity and Going Concern Considerations [Line Items]
Number of shares of common stock for which warrant is exercisable (in shares) | shares				9,900,990,000,000
Exercise price of warrant (in dollars per share) | $ / shares				$ 1.39
Warrant price (dollars per share) | $ / shares				$ 0.125
Registered Direct Offering
Liquidity and Going Concern Considerations [Line Items]
Number of shares issued | shares				844,613
Common stock trading price (in dollars per share) | $ / shares				$ 1.39
Registered Direct Offering | Registered Direct Offering Warrants
Liquidity and Going Concern Considerations [Line Items]
Exercise price of warrant (in dollars per share) | $ / shares				$ 0.0001
Cantor Fitzgerald & Co | Controlled Equity Offering
Liquidity and Going Concern Considerations [Line Items]
Sale of stock, aggregate consideration authorized										$ 12,200,000
Number of shares issued | shares						7,500
Consideration received						$ 15,135
Weighted-average selling price (dollars per share) | $ / shares						$ 2.02
Stock issuance costs						$ 378
Da Vita Healthcare Partners Inc | Share Issuance, Tranche One
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock					7,500,000
Da Vita Healthcare Partners Inc | Share Issuance, Tranche Two
Liquidity and Going Concern Considerations [Line Items]
Proceeds from issuance of convertible preferred stock	$ 7,500,000	$ 7,500,000
Da Vita Healthcare Partners Inc | Private Placement | Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Sale of stock, aggregate consideration authorized					$ 15,000,000
Consideration received			$ 15,000,000
Common stock trading price (in dollars per share) | $ / shares					$ 1,000
Da Vita Healthcare Partners Inc | Private Placement | Share Issuance, Tranche One | Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Number of shares issued | shares					7,500
Da Vita Healthcare Partners Inc | Private Placement | Share Issuance, Tranche Two | Series X Convertible Preferred Stock
Liquidity and Going Concern Considerations [Line Items]
Number of shares issued | shares	7,500	7,500